TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07629960: A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations

Sponsor: Blueprint Medicines Corporation · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 265 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$9,581,880

Rescue Site Savings

+$6,322,470

Unlock Full NCT07629960 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07629960 Rescue Dossier →